BioStock Investor Pitch: Alligator Bioscience

Alligator Bioscience has been off to a hot start in 2023. First came the positive interim results from the phase II study in pancreatic cancer. Then, the first patient was dosed in a phase I study for the treatment of solid tumours in a collaboration with Aptevo Therapeutics. Now the company is carrying out a rights issue of approximately 199 million SEK. Alligator’s CEO Søren Bregenholt tells us more about ongoing activities in a BioStock Investor Pitch today at 09.15 am. 

Watch the presentation by Søren Bregenholt at biostock.se:

https://www.biostock.se/en/2023/05/biostock-investor-pitch-alligator-bioscience/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

This material has been prepared for marketing purposes and is not and should not be considered a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and more information about the company have been presented in the EU Growth Prospectus published at alligatorbioscience.se on 26 April 2023. The EU Growth Prospectus has been approved and registered by the Financial Supervisory Authority. The marketing material is not intended to replace the EU growth prospectus as a basis for decisions to subscribe to shares in Alligator Bioscience and does not constitute a recommendation to subscribe to shares in Alligator Bioscience. Investors intending or considering investing in Alligator Bioscience are therefore advised to read the EU growth prospectus.